Table 1.
Univariable Cox proportional hazards analysis of survival based on genetic aberration in the two cohorts
| Genetic aberration | Overall survival in discovery cohort | Overall survival in validation cohort | Radiographic progression-free survival in discovery cohort | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | |
| AR aberration | 3.87 (2.21–6.77) | < 0.001 | 2.26 (1.43–3.58) | <0.001 | 1.86 (1.07–3.24) | 0.028 |
| TP53 aberration | 3.55 (2.07–6.08) | < 0.001 | 2.18 (1.37–3.47) | 0.001 | 1.80 (1.01–3.13) | 0.039 |
| RB1 deletion | 4.10 (2.33–7.22) | < 0.001 | 1.79 (1.09–2.94) | 0.021 | 3.08 (1.64–5.79) | < 0.001 |
| PI3K aberration | 2.66 (1.55–4.58) | < 0.001 | 2.11 (1.33–3.34) | 0.002 | 2.53 (1.42–4.49) | 0.001 |
All p-values < 0.05 are highlighted in bold
Data regarding radiographic progression-free survival was not available for the validation cohort
CI confidence interval, HR hazard ratio, PI3K phosphatidylinositol-3-kinase